<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473263</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01030-47</org_study_id>
    <nct_id>NCT02473263</nct_id>
  </id_info>
  <brief_title>Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock</brief_title>
  <acronym>SSS</acronym>
  <official_title>Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an aggressive strategy of severe sepsis
      patients since pre hospital care, including early antibiotics administration, hemodynamic
      optimization, and opotherapy when indicated, could reduce mortality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major prognostic factor in sepsis management is rapidity of treatments implementation. In
      2001, Rivers observed a reduction in mortality through early hemodynamic optimization. In
      2009, Arnold emphasizes that establishing more early antibiotic therapy allowed a further
      reduction of mortality.

      In France, pre hospital care is based on mobile intensive care unit (MICU) called SMUR. SMUR
      is consisting of a driver, a nurse and an emergency physician.

      Actually in France, management of severe septic syndrome (severe sepsis and septic shock) are
      not standardized and based on a &quot;conventional&quot; strategy at the discretion of the emergency
      physician. Antibiotics are given in only two cases: fulminans purpura and meningitis.
      Hemodynamic optimization is not a standard of care and no recommendation exist for
      hemodynamic targets.

      An &quot;aggressive&quot; strategy based on early antibiotics administration, hemodynamic optimization
      and opotherapy when required could be initiated by SMUR since first contact with the patient
      before hospital admission.

      We assume that an &quot;aggressive&quot; strategy initiated during the first 60 minutes of prehospital
      stage compared to &quot;conventional&quot; strategy could allow to reduce mortality in severe sepsis
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of death</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death</measure>
    <time_frame>at hospital discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stay in intensive care unit</measure>
    <time_frame>at Intensive Care Unit discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stay at hospital</measure>
    <time_frame>at hospital discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of vasopressor support</measure>
    <time_frame>at Intensive Care Unit discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of mechanical ventilation support</measure>
    <time_frame>at Intensive Care Unit discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of renal replacement therapy</measure>
    <time_frame>at Intensive Care Unit discharge time, estimated at 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antibiotic administration and no hemodynamic target are required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome</description>
    <arm_group_label>Aggressive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin tazobactam</intervention_name>
    <description>Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome</description>
    <arm_group_label>Aggressive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading</description>
    <arm_group_label>Aggressive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h</description>
    <arm_group_label>Aggressive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients fulfilling the following criteria:

          -  Age ≥ 18 years

          -  Patient with suspected severe infection defined by the existence of a suspected
             infection AND

               -  Hypotension before vascular fluid loading AND/OR

               -  Lactataemia greater than 4 mmol/l AND/OR

               -  Glasgow scale lower than 13 AND/OR

               -  Mottling score greater than 2

          -  Patient with a septic shock

        Exclusion Criteria:

          -  Age &lt;18 years or Unable

          -  Pregnant

          -  Severe concomitant pathology requiring urgent care(i.e.epilepsy)

          -  Status &quot;not to be reanimated&quot;

          -  Fulminans purpura

          -  True allergy to beta-lactam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain Jouffroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital - 149 rue de Sèvres 75015 Paris - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romain Jouffroy, MD</last_name>
    <phone>+33 1 44 49 54 07</phone>
    <email>romain.jouffroy@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Fauroux, Master</last_name>
    <phone>+33 1 58 41 12 13</phone>
    <email>valerie.fauroux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Jouffroy, MD</last_name>
      <phone>+33 1 44 49 54 07</phone>
      <email>romain.jouffroy@nck.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <reference>
    <citation>Pottecher T, Calvat S, Dupont H, Durand-Gasselin J, Gerbeaux P; SFAR/SRLF workgroup. Haemodynamic management of severe sepsis: recommendations of the French Intensive Care Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris, France. Crit Care. 2006;10(4):311.</citation>
    <PMID>16941754</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96.</citation>
    <PMID>16625125</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008 Jan;34(1):17-60. Epub 2007 Dec 4. Erratum in: Intensive Care Med. 2008 Apr;34(4):783-5.</citation>
    <PMID>18058085</PMID>
  </reference>
  <reference>
    <citation>Sebat F, Johnson D, Musthafa AA, Watnik M, Moore S, Henry K, Saari M. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest. 2005 May;127(5):1729-43.</citation>
    <PMID>15888853</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe septic syndrome</keyword>
  <keyword>mobile intensive care unit</keyword>
  <keyword>strategy</keyword>
  <keyword>antibiotics</keyword>
  <keyword>hemodynamic optimization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

